Colin Belliveau

[Colin Belliveau @ColinBelliveau_]

🔬 PSMA-PET vs MRI in Prostate Cancer for RT dose escalation.

✅ Findings:
- MRI outperforms PSMA-PET for intermediate-risk PCa.
- PSMA-PET may add value for high-risk patients

⚠️ Caution: PSMA-PET shows lower specificity in intermediate-risk PCa.

https://t.co/jwiZEOK3Ue

[UroToday.com @urotoday]

Randomized controlled trial of PSMA-PET image-guided intensification of salvage radiotherapy after radical prostatectomy: Which patients are most likely to benefit and other secondary analyses - @ColinBelliveau_ @chumontreal. #ASTRO24 coverage > https://t.co/BjAJiOl9Mv @RKSayyid

[UroToday.com @urotoday]

Role of brachytherapy for unfavorable intermediate-risk #ProstateCancer. Presentation by @cynthiamenardRO @chumontreal. #ASTRO24 written coverage by @chavarriagaj @UofT > https://t.co/WTfsLIDTYN @ASTRO_org

[UroToday.com @urotoday]

PSMA-PET guided intensification of salvage radiotherapy after radical prostatectomy: a phase 2 randomized controlled trial. Presentation by Colin Belliveau, MD @chumontreal. #EAU24 written coverage by @RKSayyid @UofT > https://t.co/EX9KdDafZy @Uroweb